Related Experiment Videos
[Endocrine therapy for prostate cancer in the future]
1Department of Urology Osaka Medical Center for Cancer and Cardiovascular Disease, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 9, 1998
Summary
Endocrine therapy for prostate cancer is evolving with new formulations of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists. Emerging anti-androgens like bicalutamide offer improved utility, expanding treatment options.
Area of Science:
- Urology
- Oncology
- Endocrinology
Context:
- Prostate cancer treatment landscape is rapidly evolving.
- Established therapies like luteinizing hormone-releasing hormone (LH-RH) agonists are seeing new long-acting formulations.
- Emerging therapeutic agents and strategies are under development.
Purpose:
- To provide an overview of the current and near-future advancements in endocrine therapy for prostate cancer.
- To highlight the introduction of novel drug formulations and agents.
- To discuss the evolving treatment strategies in prostate cancer management.
Summary:
- New long-acting formulations of LH-RH agonists are nearing clinical introduction in Japan.
- LH-RH antagonists, previously limited by adverse reactions, are also poised for practical use.
- Bicalutamide, a promising anti-androgen, is under regulatory review, suggesting enhanced therapeutic potential.
- Research is exploring a wider array of endocrine therapies and treatment modalities, including patient selection, timing, and combination therapies.
Impact:
- These advancements promise to expand therapeutic options for prostate cancer patients.
- The introduction of novel formulations and agents may improve treatment efficacy and patient compliance.
- Evolving treatment strategies aim to optimize outcomes in prostate cancer care.